
ANI Pharmaceuticals, Inc.: updates and filings
Price
$69.13
November 19, 2026Market cap $1.6B
What Ploutos Investor adds for ANI Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 8, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Regulation FD disclosureForm8-K
- Nov 5, 2026Material agreement entered, new material financial obligation, other material eventsForm8-K
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operations, Regulation FD disclosureForm8-K
- Aug 24, 2026Officer or director changeForm8-K
- Aug 7, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 7, 2026Results of operations, Regulation FD disclosureForm8-K
- Jul 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 17, 2026Shares registered for employeesFormS-8
- May 21, 2026Officer or director change, shareholder voteForm8-K
- May 13, 2026Regulation FD disclosureForm8-K
- May 8, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 8, 2026Results of operationsForm8-K
- Apr 9, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 9, 2026Additional annual meeting materialFormDEFA14A
- Apr 9, 2026Annual meeting proxy statementFormDEF 14A
- Apr 7, 2026Change of auditorForm8-K
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 3, 2026Regulation FD disclosureForm8-K
- Feb 27, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 27, 2026Results of operationsForm8-K
- Jan 12, 2026Results of operations, Regulation FD disclosureForm8-K
- Dec 1, 2025Officer or director change, Regulation FD disclosureForm8-K
- Nov 13, 2025Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 10, 2025Results of operations, Regulation FD disclosureForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 5, 2026 | 8-K | Material agreement entered, new material financial obligation, other material events | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Aug 24, 2026 | 8-K | Officer or director change | Document |
| Aug 7, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 7, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jul 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 17, 2026 | S-8 | Shares registered for employees | Document |
| May 21, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 13, 2026 | 8-K | Regulation FD disclosure | Document |
| May 8, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 8, 2026 | 8-K | Results of operations | Document |
| Apr 9, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 9, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 9, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 7, 2026 | 8-K | Change of auditor | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 3, 2026 | 8-K | Regulation FD disclosure | Document |
| Feb 27, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 27, 2026 | 8-K | Results of operations | Document |
| Jan 12, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Dec 1, 2025 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Nov 13, 2025 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 10, 2025 | 8-K | Results of operations, Regulation FD disclosure | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Dec 23, 1999.
The full analysis
What do ANI Pharmaceuticals's filings show?
The filings are where every one of ANI Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.